RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases
Joined December 2014
- Tweets 742
- Following 626
- Followers 1,336
- Likes 7
151 Photos and videos
#RDHL’s #opaganib receives @FDA rare pediatric disease designation for neuroblastoma, with potential for #PriorityReviewVoucher. Adds to prior #orphandrugdesignation. $RDHL PR: bit.ly/4vCodhV
1
49
$RDHL has commenced recognition and enforcement proceedings in #Korea for the $11 million #NewYork #SupremeCourt final judgment in favor of #RDHL against #Kukbo. Press release: bit.ly/4ogSaBS
57
#RDHL advancing #opaganib options for #Ebola biodefense platforms, incl. @WHO’s SOLIDARITY CORE clinical trial platform & pharma collaborations, amid rapidly evolving #Bundibugyo #EVD outbreak, which has no approved medications or vaccines. $RDHL PR: bit.ly/4fUPffW
1
5
819
Apr 30
#RDHL’s RHB-204 comparable MAP killing efficacy to RHB-104, with lower doses. Key step in RHB-204’s FDA-guided path to potential groundbreaking MAP-related approach to #Crohns. Multiple FDA designations, possible PRV and regulatory exclusivities. $RDHL PR: bit.ly/3PcoCrV
1
4
505
Apr 22
New preclinical data presented @AACR #AACR2026 annual meeting shows positive effects of #RDHL’s #opaganib as potential add-on therapy in models of #neuroblastoma (#NB) and triple-negative #breastcancer (#TNBC). $RDHL PR: bit.ly/4vJ6IgZ
1
2
253
Feb 25
#RDHL announces the start of joint U.S. commercialization of #Talicia with Cumberland ($CPIX), with full sales and operational launch commencing to support accelerated market penetration and expanded reach. $RDHL PR: bit.ly/4aGi5wg
1
3
261
15 Dec 2025
#RDHL’s opaganib plus venetoclax halves number of venetoclax-resistant #CLL #cancer cells in vivo compared to control – potential as add-on therapy to $2.5B blockbuster in emerging venetoclax-resistant CLL therapeutic challenge. $RDHL PR: bit.ly/3L3GqDz @GamberaleRomina
1
1
3
232
1 Dec 2025
$RDHL successfully regains compliance with the @Nasdaq stockholders’ equity requirement. #RDHL PR: bit.ly/4iqrfk0
3
295
4 Nov 2025
$RDHL’s $10.5 million New York Supreme Court judgment win now final for enforcement. No further appeal permissible. 9% annual statutory interest continues to accrue on award. #RDHL PR: bit.ly/47WQgzC
1
291
20 Oct 2025
$RDHL secures $4 million strategic investment & U.S. co-commercialization partnership with $CPIX (Cumberland) for a 30% stake in #RDHL’s #Talicia business & shared net revenues - set to accelerate sales growth & deliver significant efficiencies. PR: bit.ly/42QLkcS
1
1
412
16 Oct 2025
#RDHL is deeply saddened by the loss of our dear friend & SAB member, Prof. Thomas Borody. He will be greatly missed, but his legacy lives on - 1st to formulate today’s gold standard triple therapy for #HPylori & paving the way for a potential game-changing #Crohnsdisease therapy
ALT Prof. Thomas Borody. Photo credit: https://nz.news.yahoo.com/lifestyle/brown-010000659.html
2
371
6 Oct 2025
$RDHL signs new $1.8 million royalties Middle East deal for #Talicia - speeds entry to new Middle East markets. #RDHL receives $0.5M guaranteed payments minimum of $1.3M in near-term milestone payments, and net sales royalties. PR: bit.ly/4gWMyZG
1
2
243
29 Sep 2025
$RDHL wins New York Supreme Court appeal, upholding $10 million summary judgment against Kukbo, unequivocally dismissing Kukbo’s defense and stating that RedHill had fulfilled all obligations. #RDHL PR: bit.ly/487tANM
3
470
20 Aug 2025
$RDHL awarded $1.8 million in legal costs and expenses by #NewYorkSupremeCourt, in addition to RedHill’s prior $8.25 million #NewYork #SupremeCourt summary judgment win. Awards include 9% ongoing statutory interest accrual. #RDHL PR: bit.ly/4mRdcoK
2
1
3
383
18 Aug 2025
#RDHL has received $1.1 million in first ex-U.S. #Talicia licensing payments. $RDHL PR: bit.ly/45mZZ11
1
1
4
366
21 Jul 2025
Positive #FDA feedback for #RDHL’s #RHB204 approval path for #Crohnsdisease. Groundbreaking: 1st in a MAP only patient group & cutting-edge MAP testing enabling smaller sample size, lower cost & faster completion; Non-dilutive funding planned. $RDHL PR: bit.ly/46h0MBD
7
3
15
1,546